首页 > 市场调查报告书 > 製药

疫苗癌症

市场调查报告书

商品编码

1807074

胜肽癌症疫苗的全球市场:市场机会，技术平台，临床试验趋势(2030年)

Global Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030

出版日期: 2025年09月01日 | 出版商:

KuicK Research | 英文 220 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球胜肽类抗癌疫苗市场：市场机会、技术平台及临床试验趋势（2030 年）报告结果及重点

全球及区域市场趋势洞察
依来源、长度和抗原决定位特异性划分的胜肽类抗癌疫苗
临床试验中的胜肽类抗癌疫苗：超过 50 种疫苗
美国在胜肽类抗癌疫苗研发领域占主导地位：超过 20 种疫苗
全球胜肽类抗癌疫苗临床试验洞察：按公司、国家、阶段和适应症划分
以公司划分的胜肽类抗癌疫苗研发技术平台洞察
综合格局

胜肽类抗癌疫苗的需求及本报告的意义

癌症仍然是全球最常见的死亡原因之一，而目前的治疗方法，例如化疗和放疗，通常伴随严重的副作用和不一致的缓解率。在这种情况下，基于胜肽的癌症疫苗可能提供一种可行的选择，以最小的毒性实现癌症的标靶免疫破坏。透过利用肿瘤特异性胜肽或新抗原胜肽，这些疫苗能够产生高度特异性的T细胞应答，其精准度可媲美免疫疗法，而无需细胞或病毒载体平台的复杂性。

本报告旨在满足日益增长的市场需求，为包括生物技术公司、投资者、医疗保健规划人员和监管机构在内的利益相关者提供有关动态癌症肽疫苗市场的实用见解。由于许多候选药物已进入临床试验阶段并即将商业化，因此，了解其现状和未来方向对于做出明智的决策至关重要。

报告中包含的临床试验见解

本报告提供了全球50多个正在进行和已完成的临床试验的详细资讯。该报告按临床试验阶段、癌症类型、治疗标靶、联合方案、申办方、合作方、技术许可方和地区细分了研发管线。值得注意的是，人们对靶向多个表位的多价疫苗以及与检查点抑制剂联合研究的胜肽疫苗的兴趣日益浓厚。

在后期临床候选药物中，SELLAS Life Sciences 的 Garinpepimut-S 目前正在进行 AML 的 III 期临床试验，并且在间皮瘤治疗中也显示出良好的前景。针对非小细胞肺癌、摄护腺癌、三阴性乳癌和胶质母细胞瘤的胜肽疫苗临床试验也正在进行中。这些试验涵盖了美国、欧盟、日本、中国和韩国等多个地区，凸显了胜肽疫苗平台的国际吸引力。

参与胜肽类癌症疫苗研发的主要公司

许多製药和生物技术公司正在开发基于胜肽的免疫疗法研发管线。主要公司包括 Scancell Holdings、SELLAS Life Sciences、ISA Pharmaceuticals、Imugene 和 BrightPath Biotherapeutics。所有这些公司都在研究单价和多价疫苗策略。

有些公司针对常见的肿瘤抗原，而有些公司则根据新一代定序结果设计客製化的肿瘤新抗原疫苗。其他公司，如 OncoTherapy Science 和 VAXON Biotech，正在建立针对 WT1、MAGE-A3 和 survivin 等抗原的癌症特异性产品线。

技术平台、合作与协议

胜肽类癌症疫苗市场越来越受到尖端技术平台和策略合作伙伴关係的影响。 Moditope®（Scancell）和 Twin®（IO Biotech）等专有平台是关键的差异化因素，可提高免疫原性和递送效率。此类平台能够改善抗原决定位呈现、活化免疫细胞，并最大限度地降低免疫逃脱风险。

合作如今对于产品线开发至关重要。许多公司已经与CDMO、学术机构和大型製药公司签署了联合开发协议。例如，SELLAS与纪念斯隆凯特琳癌症中心合作开发其GPS疫苗，此外，还有许多公司正在与欧洲和亚洲的区域製造伙伴合作，以提高GMP生产能力。允许肽库和免疫资讯学工具交换的许可协议也在增加。

报告展示了胜肽类癌症疫苗领域的未来发展方向

报告指出，癌症胜肽疫苗的未来前景广阔，但竞争激烈。目前，Riavax是韩国唯一获批的胜肽类疫苗，儘管其概念被证明有效，但其批准随后被撤销。然而，自那时起，该领域的科学研究已取得显着进展，包括增强抗原发现、更有效率的患者分层以及转向联合疗法。

该领域的命运很可能由多表位疫苗和人工智慧及大数据分析赋能的新抗原个体化治疗所掌控。商业利益很可能在胶质母细胞瘤、胰臟癌和难治性未满足需求等尚未满足的适应症中成长。随着监管机构为免疫疗法审批提供明确的指导方针并整合真实世界数据，未来三到五年内，几种处于后期研发阶段的胜肽类疫苗或将获得批准。

本报告以数据为依据，深入洞察肽类癌症疫苗的创新趋势、临床试验进展、合作、商业化管道等，使其成为希望在该领域保持领先地位的利益相关者的必读之作。

Global & Regional Market Trends Insight
Peptide Cancer Vaccine Classification By Source, Length & Epitope Specificity
Peptide Cancer Vaccines In Clinical Trials: > 50 Vaccines
US Dominating Peptide Cancer Vaccines Development Landscape: > 20 Vaccines
Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase & Indication
Insight On Peptide Cancer Vaccine Development Technology Platforms By Companies
Completive Landscape

Peptide Cancer Vaccine Need & Why This Report?

Cancer remains among the most common causes of death globally, and current therapies like chemotherapy and radiation are frequently associated with serious side effects and inconsistent response rates. In such an instance, peptide based cancer vaccines could offer a viable option for targeted immune mediated cancer destruction with less toxicity. Such vaccines utilize tumor specific or neoantigenic peptides to generate extremely specific T-cell responses with the precision of immunotherapy without the intricacy of cell or viral vector platforms.

This report is aimed at filling an expanding market need by delivering stakeholders, including biotech firms, investors, healthcare planners, and regulators, with practical insights into the dynamic cancer peptide vaccine market. With a number of candidates undergoing clinical trials and nearing commercialization, insight into the current situation and future direction is necessary for intelligent decision making.

Clinical Trials Insight Included In Report

The report delivers in-depth information from more than 50 ongoing and completed clinical trials from all over the globe. It provides a breakdown of the pipeline by trial phase, cancer type, therapeutic target, and combination regimen, as well as sponsors, collaborators, technology licensors, and geographic regions. Interestingly, there is heightened interest in multivalent vaccines acting on several epitopes as well as peptide vaccines under investigation with checkpoint inhibitors.

Among the late stage clinical contenders, SELLAS Life Sciences' Galinpepimut-S is in a Phase III trial for AML and has also been active in mesothelioma. Other ongoing trials involve peptide vaccines in NSCLC, prostate cancer, triple-negative breast cancer, and glioblastoma. The trials cover a number of geographies, such as the US, EU, Japan, China, and South Korea, highlighting the international appeal of peptide vaccine platforms.

Leading Companies Engaged In R&D Of Peptide Cancer Vaccine

There are numerous biotechnology companies as well as pharmaceutical firms that are developing peptide based immunotherapy pipelines. Some of the key players are Scancell Holdings, SELLAS Life Sciences, ISA Pharmaceuticals, Imugene, and BrightPath Biotherapeutics. They are all working on both monovalent and polyvalent vaccine strategies.

Every firm has its own distinct approach; some aim at common tumor antigens, whereas others design customized neoantigen vaccines based on next-generation sequencing results. Then there are participants such as OncoTherapy Science and VAXON Biotech that are creating cancer-specific pipelines, in general, aimed at antigens such as WT1, MAGE-A3, or survivin.

Technology Platforms, Collaborations & Agreements

The peptide cancer vaccine market is more and more influenced by cutting-edge technology platforms and strategic partnerships. Exclusive platforms like Moditope(R) (Scancell) and T-win(R) (IO Biotech) are the main differentiators that improve immunogenicity and delivery efficacy. Such platforms allow improved epitope presentation, activation of immune cells, and minimizing the risk of immune escape.

Collaborations are now essential to the advancement of pipelines. Numerous companies are entering co-development deals with CDMOs, academic institutions, or bigger pharma partners. For instance, SELLAS has collaborated with Memorial Sloan Kettering for its GPS vaccine, and various companies are collaborating with regional manufacturing partners in Europe and Asia for ramping up GMP production. Licensing deals are also increasing, allowing the exchange of peptide libraries and immunoinformatics tools among partners.

Report Indicating Future Direction Of Peptide Cancer Vaccine Segment

The report suggests a very promising but competitive future for cancer peptide vaccines. Although Riavax is currently the sole peptide vaccine that has obtained market approval in South Korea, which was subsequently withdrawn, it demonstrated the validity of the concept. The science has developed considerably since, however, with enhanced antigen discovery, more efficient stratification of patients, and a move towards combination forms of therapy.

The destiny of this space will most probably be controlled by multiepitope vaccines and neoantigen personalization enabled by AI and big data analysis. Commercial interest is likely to increase in unmet need indications like glioblastoma, pancreatic cancer, and refractory NSCLC. With regulatory agencies offering clearer guidelines for immunotherapy approvals and integration of real-world data, some late-stage peptide vaccines may receive approvals in the next 3-5 years.

This report is a must read for stakeholders looking to ride the increasing tide in this space, providing data-driven insights on innovation trends, trial updates, collaborations, and commercialization channels in the landscape of peptide cancer vaccines.

1. Introduction To Peptide Cancer Vaccines

1.1 Overview & Historical Context
1.2 Peptide Based Immunotherapy In Oncology

2. Need For Peptide Cancer Vaccines

2.1 Why Peptides Are More Desirable In Cancer Immunotherapy
2.2 Peptide Vaccines vs. Traditional Cancer Vaccines
2.3 Gaps Addressed By Peptide Vaccines

3. Peptide Cancer Vaccines Mechanism Of Action

4. Classification Of Peptide Cancer Vaccines

4.1 Based On Source Of Peptides
4.2 Based on Peptide Length
4.3 Based on Epitope Specificity

5. Peptide Cancer Vaccines Development & Clinical Trends By Indication

5.1 Brain Cancer
5.2 Breast Cancer
5.3 Lung Cancer
5.4 Skin Cancers
5.5 Gastrointestinal Cancers
5.6 Gynecologic Cancers

6. Global Peptide Cancer Vaccine Market Overview

6.1 Current Market Landscape
6.2 Future Outlook & Innovation Opportunities

7. Global Peptide Cancer Vaccine Market Development Trends By Region

7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 South Korea

8. Global Peptide Cancer Vaccine Pipeline Overview

8.1 By Country
8.2 By Company
8.3 By Indication
8.4 By Phase

9. Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase & Indication

9.1 Preclinical
9.2 Phase-I
9.3 Phase-I/II
9.4 Phase-II
9.5 Phase-III

10. Global Peptide Cancer Vaccine Market Dynamics

10.1 Key Drivers & Opportunities
10.2 Market Challenges & Limitations

11. Technology Platforms For Peptide Cancer Vaccine Development By Companies

12. Competitive Landscape

12.1 3D Medicines
12.2 BrightPath Biotherapeutics
12.3 Circio Holding
12.4 Cecava
12.5 Dx&Vx
12.6 Elicio
12.7 Evaxion
12.8 GemVax & KAEL
12.9 IO Biotech
12.10 ISA Pharmaceuticals
12.11 OncoTherapy Science
12.12 OSE Immunotherapeutics
12.13 Nouscom
12.14 Nykode Therapeutics
12.15 Scancell
12.16 SELLAS Life Sciences
12.17 Seqker Biosciences
12.18 Shionogi
12.19 Vaxon Biotech
12.20 Zelluna

简介目录图表

List of Figures

Figure 1-1: Peptide Cancer Vaccine Development - Key Milestones
Figure 1-2: Personalized Peptide Vaccines Based On Neoantigens
Figure 1-3: Peptide-Based Cancer Immunotherapy Mechanism
Figure 1-4: Dual Pathway Activation Via Peptides
Figure 1-5: Peptide Delivery Technologies
Figure 1-6: Peptide Combination Therapies
Figure 1-7: Peptide Immunotherapy - Challenges vs Solutions
Figure 2-1: Benefits of Peptides in Immunotherapy
Figure 2-2: Tumor Types & Peptide Targets
Figure 2-3: Multifunctional Peptides In Immunotherapy
Figure 2-4: Peptide-Based Immunotherapies In Global Health
Figure 2-5: Antigen Loss & Immune Escape vs Multi-Epitope Vaccination
Figure 3 1: Peptide Cancer Vaccines - Mechanism Of Action
Figure 4-1: Tumor-Associated Antigen Sources
Figure 4-2: Neoantigen Generation Sources
Figure 4-3: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines - Microenvironment Impact
Figure 4-4: Short Peptides - Pros & Cons
Figure 4-5: Long Peptides - Pros & Cons
Figure 4-6: Short & Long Peptide Vaccines - Antigen Processing & Presentation Pathways
Figure 4-7: CD8+ T Cell Activation Functional Outcomes
Figure 4-8: CD4+ T Cell Activation Functional Outcomes
Figure 4-9: MHC Class I & II - Antigen Processing Pathways
Figure 5-1: SURVIVE Phase II (NCT05163080) Study - Initiation & Estimated Completion Year
Figure 5-2: NCI-2015-00694 Phase II (NCT02455557) Study - Initiation & Estimated Completion Year
Figure 5-3: CONNECT1906 Phase II (NCT05096481) Study - Initiation & Estimated Completion Year
Figure 5-4: PRO13110086 Phase II (NCT02358187) Study - Initiation & Estimated Completion Year
Figure 5-5: PRO12050422 Phase I (NCT01795313) Study - Initiation & Estimated Completion Year
Figure 5-6: FLAMINGO-01 Phase III (NCT05232916) Study - Initiation & Estimated Completion Year
Figure 5-7: Pro00104868 Phase I (NCT04270149) Study - Initiation & Estimated Completion Year
Figure 5-8: CTO-IUSCCC-09138 Phase I (NCT06414733) Study - Initiation & Estimated Completion Year
Figure 5-9: 16-132 Phase I (NCT02826434) Study - Initiation & Estimated Completion Year
Figure 5-10: NCI-2016-01878 Phase II (NCT03012100) Study - Initiation & Estimated Completion Year
Figure 5-11: ARTEMIA Phase III (NCT06472245) Study - Initiation & Estimated Completion Year
Figure 5-12: PNeoVCA Phase I/II (NCT05269381) Study - Initiation & Estimated Completion Year
Figure 5-13: J23120 Phase I/II (NCT05950139) Study - Initiation & Estimated Completion Year
Figure 5-14: AMPLIFY-201 Phase I (NCT04853017) Study - Initiation & Estimated Completion Year
Figure 5-15: 18-279 Phase I (NCT03929029) Study - Initiation & Estimated Completion Year
Figure 5-16: KEYNOTE-D18 Phase III (NCT05155254) Study - Initiation & Estimated Completion Year
Figure 5-17: AMPLIFY-7P Phase I/II (NCT05726864) Study - Initiation & Estimated Completion Year
Figure 5-18: OBERTO-301 Phase II (NCT05243862) Study - Initiation & Estimated Completion Year
Figure 5-19: TEDOPAM Phase II (NCT03806309) Study - Initiation & Estimated Completion Year
Figure 5-20: GO-010 Phase II/III (NCT05141721) Study - Initiation & Estimated Completion Year
Figure 5-21: AMC-099 Phase III (NCT03284866) Study - Initiation & Estimated Completion Year
Figure 5-22: SAHoWMU-CR2024-07-107 Phase II/III (NCT06341907) Study - Initiation & Estimated Completion Year
Figure 5-23: GINECO-OV244b Phase II (NCT04713514) Study - Initiation & Estimated Completion Year
Figure 6-1: Global Cancer Peptide Vaccine Market - Future Opportunities
Figure 8-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2025 Till 2030
Figure 8-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2025 Till 2030
Figure 8-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Indication, 2025 Till 2030
Figure 8-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2025 Till 2030
Figure 10-1: Global Cancer Peptide Vaccine Market - Market Drivers & Opportunities
Figure 10-2: Global Cancer Peptide Vaccine Market - Market Challenges & Limitations
Figure 11-1: Cecava - Personalized Neoepitope Peptide Vaccine Platform
Figure 11-2: IO Biotech - T-win
Figure 11-3: ISA Pharmaceuticals - SLP Technology

List of Tables

Table 2-1: Peptide Vaccines vs. Traditional Cancer Vaccines
Table 2-2: Gaps In Cancer Treatment Addressed By Peptide Vaccines
Table 4-1: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines
Table 4-2: Short vs Long Peptide Vaccines
Table 4-3: Short vs Long Peptide Vaccines - Ideal Candidate Use Scenarios
Table 4-4: MHC Class I vs MHC Class II Peptide Vaccines
Table 4-5: MHC-I & MHC-II Vaccines - Unique & Overlapping Features

02-2729-4219

+886-2-2729-4219

License/价格

胜肽癌症疫苗的全球市场:市场机会，技术平台，临床试验趋势(2030年)

Global Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030

目录

第1章胜肽癌症疫苗的简介

第2章胜肽癌症疫苗的必要性

第3章胜肽癌症疫苗的作用机制

第4章胜肽癌症疫苗的分类

第5章胜肽类癌症疫苗的开发及各适应症的临床趋势

第6章全球胜肽癌症疫苗市场概要

第7章各地区胜肽癌症疫苗市场开拓趋势

第8章全球胜肽癌症疫苗开发平台(管线)概要

第9章胜肽癌症疫苗的临床试验相关各企业，各国，各期，各适应症的洞察

第10章全球胜肽癌症疫苗市场动态

第11章各企业胜肽癌症疫苗开发的技术平台

第12章竞争情形